Regeneron drug reduces deaths

A cocktail of synthetic antibodies reduces deaths among severe Covid patients who are unable to mount a strong immune response, results from a major clinical trial showed. The therapy, developed by the US President Donald Trump during his brush with the coronavirus, had previously only been used to treat patients in the early stages of the disease. But the recovery trial based in Britain has found the drug is effective in treating some patients with more acute cases of the virus. The treatment, called REGN-COV2, reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own, the researchers said in a press release.

Categories: News